Nov 22 (Reuters) - Halozyme Therapeutics Inc ( HALO ):

* HALOZYME WITHDRAWS PROPOSAL TO ACQUIRE EVOTEC FOLLOWING

EVOTEC'S

UNWILLINGNESS TO ENGAGE IN DISCUSSIONS

* REITERATE RAISED 2024 GUIDANCE FOR REVENUE OF $970-$1,020

MILLION AND ADJUSTED EBITDA OF $595-$625 MILLION

* TO DATE, EVOTEC HAS BEEN UNWILLING TO ENGAGE WITH US TO

EXPLORE

A POTENTIAL COMBINATION AND A COMPANY SPOKESPERSON HAS PUBLICLY

COMMENTED THAT ITS GOAL IS TO REMAIN AN INDEPENDENT COMPANY

Source text:

Further company coverage:

(Gdansk Newsroom)

;))